Furey Raymond J.
Known title: EVP, GC, CCO & Corp SecCIK: 0001577899
Associated companies
Transaction History
| RIGL | ▼ Sell | Tax Withholding | 877 | $42K | 9/1/2026 | View on chart |
| RIGL | ▼ Sell | Tax Withholding | 877 | $26K | 6/1/2026 | View on chart |
| RIGL | ▲ Buy | Grant | 19,497 | $0 | 2/17/2026 | View on chart |
| RIGL | ▼ Sell | Tax Withholding | 3,546 | $123K | 2/10/2026 | View on chart |
| RIGL | ▼ Sell | Tax Withholding | 3,968 | $143K | 2/2/2026 | View on chart |
| RIGL | ▼ Sell | Open Market | 1,339 | $29K | 2/5/2025 | View on chart |
| RIGL | ▼ Sell | Open Market | 1,448 | $30K | 2/4/2025 | View on chart |
| RIGL | ▲ Buy | Grant | 19,717 | $0 | 1/29/2025 | View on chart |
| RIGL | ▲ Buy | Grant | 209,000 | $0 | 1/23/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RIGL: No Recent Company-Specific News Identified
Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.
RIGL: No Recent Company-Specific News Identified. Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.